Literature DB >> 31161538

Erdafitinib: First Global Approval.

Anthony Markham1.   

Abstract

Erdafitinib (Balversa™, Janssen Pharmaceutical Companies) is a pan-fibroblast growth factor receptor (FGFR) inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. The drug is also being investigated as a treatment for other cancers including cholangiocarcinoma, liver cancer, non-small cell lung cancer, prostate cancer, lymphoma and oesophageal cancer. This article summarizes the milestones in the development of erdafitinib leading to this first approval for the treatment of urothelial carcinoma.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31161538     DOI： 10.1007/s40265-019-01142-9

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  24 in total

Review 1.  The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies.

Authors:  Andres Garcia-Sampedro; Gabriella Gaggia; Alexander Ney; Ismahan Mahamed; Pilar Acedo
Journal:  J Clin Med       Date:  2021-02-03       Impact factor: 4.241

Review 2.  Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects.

Authors:  Mohammed I El-Gamal; Seyed-Omar Zaraei; Moustafa M Madkour; Hanan S Anbar
Journal:  Molecules       Date:  2022-01-05       Impact factor: 4.411

Review 3.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

4.  Genome-wide identification and analysis of prognostic features in human cancers.

Authors:  Joan C Smith; Jason M Sheltzer
Journal:  Cell Rep       Date:  2022-03-29       Impact factor: 9.995

5.  Molecular Mechanisms of Hepatoblastoma.

Authors:  Yi Zhang; Antonio Solinas; Stefano Cairo; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Semin Liver Dis       Date:  2021-01-20       Impact factor: 6.115

Review 6.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

Review 7.  Precision oncology in urothelial cancer.

Authors:  Elizabeth Liow; Ben Tran
Journal:  ESMO Open       Date:  2020-03

Review 8.  Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.

Authors:  Laura Pacini; Andrew D Jenks; Nadia Carvalho Lima; Paul H Huang
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

9.  First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.

Authors:  Sung-Bae Kim; Funda Meric-Bernstam; Aparna Kalyan; Aleksei Babich; Rong Liu; Takahiko Tanigawa; Anette Sommer; Motonobu Osada; Frank Reetz; Dirk Laurent; Sabine Wittemer-Rump; Jordan Berlin
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

Review 10.  In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs.

Authors:  Zarko Gagic; Dusan Ruzic; Nemanja Djokovic; Teodora Djikic; Katarina Nikolic
Journal:  Front Chem       Date:  2020-01-08       Impact factor: 5.221
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.